Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376: 2147-2159.

Published: 14th June 2017

Authors: Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I et al.

Conclusion

Some 910 women were included in the study. Capecitabine improved five-year disease-free survival (hazard ratio 0.70, 95 per cent confidence interval 0.53 to 0.92, P=0.01), and overall survival (0.59, 0.39 to 0.9, P=0.01).

Pubmed Link

Your comments

0 Comments